Nitto Denko Of Japan Buys U.S. CMO Avecia Biotechnology
This article was originally published in PharmAsia News
Japan's Nitto Denko said it has bought U.S.-based Avecia Biotechnology, a contract manufacturing organization specializing in nucleic acid drugs
You may also be interested in...
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.